A Study of MEN2501 in People With Ovarian Cancer

Full Title

A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants with Platinum-Resistant Ovarian Cancer

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Prashasti Agrawal’s office at 646-888-4425.

Protocol
26-241
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Prashasti Agrawal
Co-Investigators
Chrisann Kyi
Diseases
Gynecologic Cancer › Ovarian Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07226427
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description